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ABSTRACT
Somatostatin (SS) and its analogs exert inhibitory effects on se-
cretive and proliferative processes of various cells via high affinity SS
receptors (SS-R). SS analogs bind with different affinity to the five
cloned SS-R subtypes. Octreotide, an octapeptide SS analog, binds
with high affinity to the SS-R subtype 2 (sst2). SS-R have been dem-
onstrated in vivo and in vitro on cells from endocrine and immune
systems. Among the lymphatic tissues, the thymus has been shown
to contain the highest amount of SS, suggesting a local functional role
of the peptide.
We investigated the SS distribution and SS-R expression pattern
in the normal human thymus using autoradiography, membrane ho-
mogenate binding studies, and RT-PCR. In addition, the effect of SS
and octreotide on growth of cultured thymic epithelial cells (TEC) was
studied.
By autoradiography, binding of [125I-Tyr0]-SS-28 and [125I-Tyr3]-
octreotide was detected in all seven thymuses studied. Specific [125I-
Tyr3]-octreotide binding was shown on membrane preparations from
thymuses, while not from cultured thymocytes. RT-PCR showed the
expression of sst1, sst2A and sst3 messenger RNA (mRNA) in the
thymic tissue, whereas sst1 and sst2A mRNAs were found in isolated
TEC. SS mRNA was present in thymic tissue and in isolated TEC. SS
and octreotide significantly inhibited 3H-thymidine incorporation in
3 of 3 and 6 of 6 TEC cultures, respectively. The percent inhibition
ranged from 38.8 to 66.8% for SS and from 19.1 to 59.5% for octreotide.
In conclusion, SS mRNA and sst1, sst2A, and sst3 mRNAs are
expressed in the normal human thymus. Cultured TEC selectively
express sst1 and sst2A mRNA and respond in vitro to SS and octreotide
administration with an inhibition of cell proliferation. These data
suggest a paracrine/autocrine role of SS and its receptors in the
regulation of cell growth in thymic microenvironment. (Endocrinology
140: 373–380, 1999)
SOMATOSTATIN (SS), a peptide hormone originally iso-lated from the hypothalamus as a GH-releasing inhib-
iting factor, has been found throughout the central nervous
system where it predominantly acts as a neurotransmitter, as
well as in widely distributed endocrine cells in other tissues
(1–3). It has diverse biological effects on cellular function,
including inhibitory effects on secretive and proliferative
processes and modulatory actions on the response of various
cells to endocrine stimulation (2–4). The various actions of SS
are mediated through five specific high affinity membrane
receptors (SS-R) (5). These receptors have been demonstrated
in vitro in normal and tumoral tissues by classical binding
techniques, in situ hybridization and RT-PCR (4, 6–8). In
addition, using radiolabeled SS analogs, several scinti-
graphic studies have shown the in vivo localization of SS-R-
positive tumors (9, 10). SS analogs bind with different affinity
to the five different SS-R subtypes (sst1–5). Octreotide, the
most extensively studied SS analog, binds with high affinity
to sst2 and with lower affinity to sst3 and sst5 (5, 8). Among
the five subtypes, sst2 seems the most important in mediating
the antisecretive effect of octreotide (11).
Like other regulatory peptides found in the brain, SS has
also been localized in lymphatic tissue (12). Among the lym-
phatic organs, the thymus from different species including
the human has been shown to contain the highest amount of
SS, suggesting a modulatory role of the peptide in this organ
(13–15). Furthermore, SS-R have been demonstrated in vitro
in various lymphatic tissues (16). Recently, a high in vivo
uptake of 111In-DTPA-d-Phe1-octreotide was shown in pa-
tients bearing thymomas and thymic carcinoids (17, 18), and
a successful treatment with octreotide was reported in one
patient with thymoma (19). The presence of SS and SS-R in
the thymus suggests their involvement in controlling the
immuno- and/or neuroendocrine functions in this organ.
Moreover, SS analog treatment of thymic tumors and related
paraneoplastic diseases might represent a new therapeutic
approach to these disorders.
The present study was designed to investigate the expres-
sion and role of SS and SS-R subtypes in the normal human
thymus. The receptor expression pattern in the thymuses was
studied in vitro by SS-R autoradiography, membrane ho-
mogenate binding studies, and RT-PCR to identify SS-R sub-
types. In addition, the in vitro effect of SS, octreotide, and the
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growth factors insulin-like growth factor I (IGF-I) and epi-
dermal growth factor (EGF) on cell proliferation was inves-
tigated in primary human thymic epithelial cell (TEC) cul-
tures. Because fibroblasts often contaminate cultures of
epithelial cells, we used a specific antibody to human fibro-
blasts (mAb ASO2) coupled with magnetic beads for the
selective removal of fibroblasts from these cultures. This new
monoclonal antibody recognizes a human fibroblast-specific
antigen located on the cell surface (20).
Materials and Methods
Samples
Thymic tissues were removed routinely from 7 patients (age range,
1 month to 16 yr) to allow adequate exposure of the heart during
cardiovascular surgery. Samples from these thymuses were used in the
present study. The protocol was in accordance with the Helsinki Doc-
trine on Human Experimentation, informed consent was obtained from
patients or their parents. All samples were histopathologically normal
and were taken fresh at the operation, quickly frozen on dry ice, and
stored at 280 C for autoradiography and RT-PCR studies. From six
thymic tissues, specimens were also used for the establishment of pri-
mary TEC cultures.
SS receptor autoradiography
Receptor autoradiography was carried out as described by Reubi et
al. (21). Briefly, 10-micrometer thick cryostat (Jung CM3000, Leica Corp.,
Germany) sections of the tissue samples were mounted onto precleaned
gelatin-coated microscope glass slides and stored at 280 C for at least
3 days before the experiment to improve the adhesion of the tissue to the
slide. As radioligands, the SS analogs [125I-Tyr3]-octreotide and [125I-
Tyr0]-SS-28 (ANAWA Laboratories, Wangen, Switzerland) were used.
Specific activities of the radioligands amounted approximately 2000
Ci/mmol. To wash out endogenous SS, the sections were preincubated
at room temperature for 10 min in 170 mm Tris-HCl (pH 7.4). Thereafter,
the sections were incubated for 60 min at room temperature in 170 mm
Tris-HCl (pH 7.4), 5 mm MgCl2, 1% BSA, 40 mg/ml bacitracin with
[125I-Tyr3]-octreotide (final concentration approximately 80–160 pmol/
liter) or [125I-Tyr0]-SS-28 (approximately 80–160 pmol/liter). Nonspe-
cific binding was determined in a sequential section in the presence of
excess unlabeled Tyr3-octreotide (1 mm) or SS-28 (1 mm), respectively.
The incubated sections were washed twice for 5 min in incubation buffer
containing 0.25% BSA and once in incubation buffer without BSA. After
a short wash with distilled water to remove salts, the sections were air
dried and exposed to Kodak X-OMAT AR or Hyperfilm-3H (Amersham,
Houten, The Netherlands) for 3–7 days in x-ray cassettes. Histology was
performed on hematoxylin-eosin stained sequential cryosections.
RT-PCR
Poly A1 mRNA was isolated using Dynabeads Oligo (dT)25 (Dynal
AS, Oslo, Norway) from cell pellets containing approximately 106 cells
or from approximately 50 mg frozen powdered tissue that was grinded
in a metal homogenizer cooled by liquid nitrogen. The cells were lysed
during 2 min on ice in a buffer containing 100 mm Tris-HCl (pH 8), 500
mm LiCl, 10 mm EDTA (pH 8), 1% LiDS, 5 mm DTT and 5 U/100 ml
RNAsin (HT Biotechnology Ltd., Cambridge, UK). The mixture was
centrifuged at 14,000 rpm for 1 min to remove cell debris. To the su-
pernatant 100 ml prewashed Dynabeads Oligo (dT)25 were added, and
the mixture was incubated for 5 min on ice. Thereafter, the beads were
collected with a magnet, washed three times with 10 mm Tris-HCl (pH
8), 0.15 m LiCl, 1 mm EDTA, 0.1% LiDS, and once with a similar buffer
from which LiDS was omitted. Poly A1 mRNA was eluted from the
beads in 50 ml of a 2 mm EDTA solution (pH 8) during 2 min at 65 C.
To avoid contamination by genomic DNA, the isolated polyA1 RNA
was subjected to a second purification by capturing the RNA on a fresh
aliquot of prewashed Dynabeads Oligo (dT)25 and washing the captured
RNA as above. Finally, the captured RNA was washed once with buffer
used for the reverse transcriptase reaction.
Complementary DNA (cDNA) was synthesized using the poly A1
mRNA captured on the Dynabeads Oligo (dT)25 in a buffer containing
50 mm Tris-HCl (pH 8.3), 100 mm KCl, 4 mm DTT, 10 mm MgCl2, 1 mm
of each deoxynucleotide triphosphate, 10 U RNAsin, and 2 U AMV
Super Reverse Transcriptase (HT Biotechnology Ltd., Cambridge, UK)
in a final volume of 20 ml. This mixture was incubated for 1 h at 41 C.
One-tenth from each cDNA library immobilized on the paramagnetic
beads was used for each amplification. The amplification reaction mix-
tures contained cDNA template, 0.5 U SuperTaq (HT Biotechnology
Ltd., Cambridge, UK), 50 mm of each deoxynucleotide triphosphate (HT
Biotechnology Ltd., Cambridge, UK), 5 pmol of each of a pair of oligo-
nucleotide primers specific for the human sst1–5 receptor subtypes, the
b-actin gene or the human SS gene (see Table 1) in a buffer of 10 mm
Tris-HCl (pH 9), 50 mm KCl, 2 mm MgCl2, 0.01% (wt/vol) gelatin, 0.1%
Triton X-100 in a final volume of 50 ml. The sequences of the primers for
sst1–5 are derived and/or adapted from Kubota et al. (8) and Wulfsen et
al. (22). The PCR reaction was carried out in a DNA thermal cycler with
heated lid (Perkin Elmer Cetus Instruments, Gouda, The Netherlands).
After an initial denaturation at 94 C for 5 min, the samples were sub-
jected to 40 cycles of denaturation at 94 C for 1 min, annealing for 2 min
at 59 C, and extension for 1 min at 72 C. After a final extension for 7 min
at 72 C, 10 ml aliquots of the resulting PCR products were analyzed by
electrophoresis on 1.5% agarose gels stained with ethidium bromide.
Several controls were included in the RT-PCR experiments. To as-
certain that no detectable genomic DNA was present in the poly A1
mRNA preparation (because the SS-R subtypes genes are intron-less),
the cDNA reactions were also performed without reverse transcriptase
and amplified with each primer-pair. Amplification of the cDNA sam-
ples with the b-actin specific primers served as positive control for the
quality of the cDNA. To exclude contamination of the PCR reaction
TABLE 1. Primers used for RT-PCR analysis
Sequence (59- 39)a Positionb Size of PCR product
Sst1 (forward) ATGGTGGCCCTCAAGGCCGG 754 318 bp
Sst1 (reverse) CGCGGTGGCGTAATAGTCAA 1071
Sst2A (forward) TCCTCTGGAATCCGAGTGGG 709 332 bp
Sst2A (reverse) TTGTCCTGCTTACTGTCACT 1040
Sst3 (forward) TCATCTGCCTCTGCTACCTG 662 221 bp
Sst3 (reverse) GAGCCCAAAGAAGGCAGGCT 882
Sst4 (forward) ATCTTCGCAGACACCAGACC 547 323 bp
Sst4 (reverse) ATCAAGGCTGGTCACGACGA 869
Sst5 (forward) CCGTCTTCATCATCTACACGG 596 223 bp
Sst5 (reverse) GGCCAGGTTGACGATGTTGA 819
Somatostatin (forward) GATGCTGTCCTGCCGCCTCCAG 1 349 bp
Somatostatin (reverse) ACAGGATGTGAAAGTCTTCCA 348
b-actin (forward) ATC CTCACCCTGAAGTACCC 190 762 bp
b-actin (reverse) GATCTCCTTCTGCATCCTGT 951
a The sequences of the primers for sst1–5 are derived and/or adapted from Kubota et al. (8) and Wulfsen et al. (22).
b The position is given of the 59 nucleotide of the primer relative to the first nucleotide of the coding region in the cDNA sequence.
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mixtures, the reactions were also performed in the absence of DNA
template in parallel with cDNA samples. As a positive control for the
PCR reactions of the SS-R receptor subtypes, 0.01 mg of human genomic
DNA was amplified in parallel with the cDNA samples. As a positive
control for the PCR of the b-actin and SS cDNA aliquots of a cDNA
sample known to contain SS (and b-actin) mRNA were amplified, be-
cause these primer-pairs did enclose introns in the genomic DNA.
Cell dispersion and cell culture
After the specimens were placed in HBSS supplemented with HSA
5% (Cealb, CLB, Amsterdam, The Netherlands), penicillin (105 U/liter),
fungizone (0.5 mg/liter), blood clots, and fibrous capsules were carefully
removed and the specimens were dissected and washed several times
with the HBSS 1 HSA. The minced tissues were enzymatically disso-
ciated with collagenase (Sigma Chemical Co., St. Louis, MO; 2 mg/ml)
for 1–2 h at 37 C. The dispersed cells were precultured for 5–7 days in
15 mg/cm2 collagen type I (Collagen S, type I, Boehringer Mannheim,
Mannheim, Germany) precoated 75-cm2 flasks (Costar, Cambridge, MA)
at a density of 5 3 106 cells/flask in 10 ml culture medium. The culture
medium, the same used during the experiments, was MEM D-valine
(Gibco BRL, Life Technologies Ltd., Paisley, Scotland, UK) supple-
mented with 10% FCS, penicillin (105 U/liter), fungizone (0.5 mg/ml),
l-glutamine (2 mmol/liter). The pH of the medium was adjusted to 7.4.
The cells were cultured at 37 C in a humid CO2-incubator. After this
period, cell viability was detected by trypan blue exclusion and varied
between 65 and 90%. The cells, which had not attached to the flasks,
mainly thymocytes, were harvested.
The isolation of TEC was indirectly performed using sheep antimouse
IgG coated magnetic beads and a ASO2 antihuman fibroblast primary
antibody kit (Dianova GmbH, Hamburg, Germany). This mouse mono-
clonal antibody reacts specifically with membrane-bound protein of
human fibroblasts of different origin (20). The magnetic beads were
coated with the specific primary antibody and mixed with the target cell
suspension to form bead rosetted cells. Rosetted cells (fibroblasts) were
collected at the tube wall and isolated using a magnetic separator rack.
For a complete negative selection, the supernatant, containing the cells
which were not bound to the beads (TEC), was treated once again with
the coated beads. The remaining suspension containing isolated TEC
was used for the experiments.
TEC (10,000–20,000 cells per well) were seeded in 1 ml culture me-
dium in 24-well collagen type I precoated plates (Costar) and allowed
to attach for 24 h. Then, tests substances were added, and the cells were
incubated for 72 h. Proliferation was measured by adding 1 mCi of
[methyl-3H]-thymidine (91 Ci/mmol; Amersham) for the last 24 h in
each well. Thereafter, the medium was removed and the cells were
washed twice with ice cold 0.9% NaCl solution and harvested using a
0.05% NH3 solution. These samples were exposed overnight to 10%
trichloroacetic acid followed by another wash with 0.9% NaCl solution.
The cells were transferred to scintillation counting vials after solubili-
zation in 1 m NaOH and incorporated radioactivity was measured, after
neutralization with HCl and the addition of scintillation fluid, in a liquid
scintillation counter (Betamatic, Packard, Downers Grove, IL). For RT-
PCR studies, TEC were seeded in collagen-coated flasks (see above) and
grown to confluence. Thereafter, the cells were harvested and mRNA
was isolated as described above.
Immunocytochemical detection of keratin on cultured TEC
For keratin staining, TEC were cultured on collagen-coated glass
coverslips. The cells were fixed for 10 min with methanol at the end of
the incubation period. Cytokeratin staining was performed with a PAP
Kit System (code K518; Dako Corp., Glostrup, Denmark). Staining for
keratin was performed after each experiment in all TEC cultures studied.
SS receptor binding studies
The method of membrane isolation and the reaction conditions were
the same as described by Reubi (23). Briefly, membrane preparations
(corresponding to 30–50 mg protein) of tissue samples, freshly dispersed
cells or cultured cells were incubated in a total volume of 100 ml at room
temperature for 60 min with increasing concentrations of [125I-Tyr3]-
octreotide with and without excess (1 mm) of unlabeled Tyr3-octreotide
in HEPES buffer (10 mm HEPES, 5 mm MgCl2 and 0.02 g/liter bacitracin,
FIG. 1. Staining for keratin of thymic
epithelial cells (TEC) cultured on cov-
erslips for the same period as TEC used
for the experiments. No fibroblasts
(keratin-negative) are present.
TABLE 2. Somatostatin and somatostatin receptor subtype
expression in human thymic tissue as determined by somatostatin
receptor-autoradiography and RT-PCR
Tissues
Somatostatin
receptor-autoradiography RT-PCR
[125I-Tyr0]
-SS-28
[125I-Tyr3]-
octreotide
sst1 sst2A sst3 sst4 sst5 SS
1 1 1 1 1 1 2 2 1
2 1 1 1 1 1 2 2 1
3 1 1 1 1 1 2 2 1
4 1 1 1 1 1 2 2 1
5 1 1 1 1 1 2 2 1
6 1 1 1 1 1 2 2 1
7 1 1 1 1 1 2 2 1
SS, Somatostatin. The experiments were performed at least twice
with identical results.
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pH 7.6) containing 0.2% BSA. After the incubation, 1 ml ice-cold HEPES
buffer was added to the reaction mixture, and membrane-bound radio-
activity was separated from unbound by centrifugation during 2 min at
14,000 rpm in a Eppendorf microcentrifuge. The remaining pellet was
washed twice in ice-cold HEPES buffer, and the final pellet was counted
in a g-counter. Specific binding was taken to be total binding minus
binding in the presence of 1 mm unlabeled Tyr3-octreotide.
Test substances
In all experiments SS-14 (Bachem, Inc., Hannover, Germany) and
octreotide (Novartis, Basle, Switzerland) were used at a concentration of
10 nm, IGF-I (Bachem, Inc.) at a concentration of 10 nm and EGF (Bachem,
Inc.) at a concentration of 10 ng/ml.
Statistical analysis
Data are expressed as mean 6 sem, n 5 4 wells per treatment group.
All data were analyzed by ANOVA to determine overall differences
between treatment groups. When significant differences were found, a
comparison between treatment groups was made using the Newman-
Keuls test. SS-R binding data were analyzed by the method of Scatchard.
Receptor binding studies and RT-PCR experiments were performed at
least twice.
Results
Fibroblast-epithelial-cell separation and staining for keratin
in cultures of TEC
The cell selection system using a mouse monoclonal an-
tibody to human fibroblasts coupled to magnetic beads en-
abled us to identify and eliminate fibroblasts from our cell
cultures to obtain 95–100% pure TEC cultures. This purity
was demonstrated by immunocytochemical staining for ker-
atin in the cultured TEC. Figure 1 shows an example of the
staining for keratin of a TEC population that was used for
the functional study (see below). Virtually no fibroblasts
(keratin-negative) were present.
SS and SS-R (subtype) expression
At autoradiography, [125I-Tyr0]-SS-28 binding was found
in the seven normal thymuses. Binding of the sst2 subtype
selective ligand [125I-Tyr3]-octreotide was in parallel positive
in all these seven cases (Table 2), and in agreement with a
previous study (16). Binding was not homogeneous and
mainly localized in the medulla (Fig. 2).
Using [125I-Tyr3]-octreotide, specific binding was demon-
strated on membrane preparations of thymic tissue, whereas
no binding was found on the cultured thymocytes. Binding
of [125I-Tyr3]-octreotide could be displaced with excess un-
labeled Tyr3-octreotide. Scatchard analysis of the binding
data revealed a single class of high affinity binding sites with
an apparent Kd ranging from 0.03 6 0.01 to 0.7 6 0.1 nm and
a low maximum binding capacity (Bmax) ranging from 3.5 6
0.5 to 18.5 6 2.5 fmol/mg membrane protein (Table 3). As a
control for binding, rat brain cortex membranes were used.
An example of saturation binding data with Scatchard anal-
ysis is shown in Fig. 3.
By RT-PCR, SS, sst1, sst2A and sst3 mRNA expression was
detected in all thymuses (example in Fig. 4; no. 5, Table 2).
Conversely, mRNA encoding for sst4 and sst5 was absent
(Table 2; Fig. 4). In cultured TEC, RT-PCR analysis showed
the presence of SS, sst1 and sst2A mRNA, while in cultured
thymocytes only mRNA for b-actin was detected (Table 4;
Fig. 4).
FIG. 2. Expression of SS-R in human thymus. Photomicrograph of
SS-R-autoradiography. A, Hematoxylin-eosin stained section; B, au-
toradiogram showing total binding of [125I-Tyr3]-octreotide; C, auto-
radiogram showing nonspecific binding (in the presence of 1 mM of
Tyr3-octreotide). Bar, 1 mm. Identical expression patterns of SS-R
were found in all cases that were studied.
TABLE 3. Somatostatin receptor expression in human thymic
tissue determined by Scatchard analysis of [125I-Tyr3]-octreotide
binding on membrane homogenates
Tissues
[125I-Tyr3]-octreotide binding
Kd (nM) Bmax (fmol/mg protein)
4 0.7 6 0.2 15.5 6 0.5
5 0.03 6 0.01 3.5 6 0.5
6 0.7 6 0.1 18.5 6 2.5
Rat brain 0.9 6 1.3 196.5 6 46.5
Kd, dissociation constant; Bmax, maximum binding capacity. The
data represent the mean 6 SEM of two independent experiments.
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In vitro effect of SS, octreotide, IGF-I and EGF on
3H-thymidine incorporation in cultured human TEC
SS (10 nm) significantly inhibited 3H-thymidine incorpo-
ration by 38.8, 61.1, and 66.8% respectively, in cultures of TEC
derived from three different normal thymuses (Fig. 5A). The
SS analog octreotide (10 nm) significantly inhibited 3H-thy-
midine incorporation by 38.7, 49.8, and 40.6%, respectively,
in these three cultures (Fig. 5A), and by 19.1, 48.2, and 59.5%
in three other additional cultures of TEC (Fig. 5B) derived
from the series of thymuses which showed [125I-Tyr3]-oct-
reotide binding at autoradiographic and membrane binding
studies. IGF-I significantly stimulated 3H-thymidine incor-
poration in two out of three cultures and EGF significantly
stimulated 3H-thymidine incorporation in all the three cul-
tures in which were tested (Table 5). Moreover, octreotide
significantly inhibited EGF-stimulated 3H-thymidine incor-
poration by 25 6 5% in one culture in which it was tested
(data not shown).
Discussion
Neuropeptide hormones produced in the brain and gas-
trointestinal tract have been found in the thymus and are
involved in the complex pattern of interactions existing be-
tween the neuroendocrine and the immune systems in this
organ (24). In fact, epithelial cell and thymocyte functions are
influenced by different hypothalamic and pituitary hor-
mones. A network between these hormones, even locally
produced, and the related receptors has been shown (25–28).
A place in this network might be hypothesized for SS and
SS-R as well. SS-R have been demonstrated in various en-
docrine and lymphatic tissues by classical biochemical bind-
ing studies (4, 6, 7, 16). In addition, SS has been demonstrated
in the thymus from different species including humans (12–
15), where it seems to be involved in the main function of the
gland (12, 13). However, the influence of SS and SS-R on the
regulation of TEC function had not been studied so far.
In the present report, we studied the distribution and the
expression of SS-R subtypes and SS in 7 normal human
thymuses. We first demonstrated specific [125I-Tyr3]-oct-
reotide binding on cryostat sections from thymic tissue,
mainly in the medulla, which is the thymic compartment
FIG. 3. Binding of [125I-Tyr3]-oct-
reotide to a membrane homogenate
preparation of a human thymus. f, to-
tal binding; , nonspecific binding in
presence of 1 mM of Tyr3-octreotide; F,
specific binding (total minus nonspe-
cific binding). Inset: Scatchard analysis
of the binding data (Kd, 0.5 nM and
Bmax, 15 fmol/mg membrane protein;
no. 4, Table 3).
FIG. 4. Heterogeneous expression of b-actin, sst1 sst2A, sst3, and SS
mRNAs in the human thymus. Poly A1 mRNA was reverse tran-
scribed and cDNA was amplified by PCR. PCR products of the sst1–5
were separated on 1% agarose gel and stained with ethidium bromide.
1, b-actin; 2, sst1; 3, sst2A; 4, sst3; 5, sst4; 6, sst5; 7, SS. M, 100-bp
ladder; A, control; B, thymic tissue; C, thymic epithelial cells; D,
thymocytes; (no. 5, Table 2). RT-PCR analysis of each tissue was
performed at least twice with identical results.
TABLE 4. Heterogeneity of somatostatin and somatostatin
receptor subtype mRNA expression in cultured human thymic
epithelial cells and thymocytes as determined by RT-PCR in 5
cases
Cell subset
RT-PCR
sst1 sst2A sst3 sst4 sst5 SS b-actin
TEC 1 1 2 2 2 1 1
Thymocytes 2 2 2 2 2 2 1
TEC, Thymic epithelial cells; SS, somatostatin. Each case was
evaluated at least two times in independent experiments and yielded
identical results.
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where the TEC is the predominant cell type, as well as in
thymic tissue homogenates. Furthermore, we characterized
the SS-R subtype expression in the same thymuses that were
used for receptor binding studies. In human thymic tissue,
we found by RT-PCR the presence of mRNA encoding for
sst1 and sst2A and sst3. The expression of the subtypes ap-
peared heterogeneous on the different cell subsets. In fact, we
found a specific binding of [125I-Tyr3]-octreotide on mem-
brane preparations from thymic tissue, whereas no binding
was found on cultured thymocytes. Interestingly, RT-PCR
showed the selective expression of sst1 and sst2A on the
cultured TEC, whereas neither SS-R subtype was found on
cultured thymocytes with this technique. Sst1 and sst2A seem
stronger expressed in the cultured TEC compared with the
thymic tissue, because with the selection method used to
establish primary TEC cultures, an enrichment of SS-R-ex-
pressing TEC was obtained. Again, it should be emphasized
that the cultured thymocytes, which represent the major
cellular component of the thymus, did not express any SS-R
subtype. Moreover, the finding that SS-R are expressed on
only a subset of the cells in the thymus also explains the
relatively low SS-R levels measured by receptor binding
studies on membrane homogenates of the whole thymic tis-
sue. Finally, this heterogeneous SS-R expression pattern in
the human thymus may also explain the apparent discrep-
ancy between the SS-R levels in the thymic tissues and the
maximal inhibitory effect of SS and octreotide on TEC
proliferation.
Furthermore, TEC seem to be the major site of SS produc-
tion in the normal human thymus. In fact, by RT-PCR we
demonstrated the presence of mRNA for SS in isolated TEC
from all the thymuses of the present series. Because our study
showed the existence of a specific SS-R subtype distribution
pattern as well as evidence for endogenous SS production in
the human thymus, we also studied the effects of SS and the
SS analog octreotide on TEC proliferation. At this purpose,
we established pure epithelial cell cultures, demonstrated by
staining for cytokeratin that showed 95–100% cytokeratin-
positive cells in all the cultures. In these human TEC cultures,
we observed a significant inhibition of cell proliferation by
SS and octreotide in all cases.
The heterogeneity of distribution of SS-R subtypes on spe-
cific cells, in combination with the endogenous production of
SS, suggest an important and dynamic regulatory role of this
peptide in the human thymus. The data of the present study
indicate that SS may exert a paracrine/autocrine inhibitory
action. This effect seems to be mediated by the sst2A and/or
sst1, which are selectively expressed on cultured TEC. The
binding of SS or its analogs to these receptor subtypes is
associated with an activation of intracellular tyrosine phos-
phatase activity (29, 30). Moreover, sst2A is also linked to cell
membrane potassium and calcium channels in a manner that
ligand binding influences the intracellular concentration of
these ions and the cell membrane polarization (31).
Although we did not investigate the expression of SS-R
and the effect of SS analogs on thymic tumoral cells, it can
be suggested that a disturbance in this pathway may play a
role in the pathogenesis of neoplastic and related autoim-
mune diseases in the human thymus. Recently, a high in vivo
uptake of 111In-DTPA-d-Phe1-octreotide was reported in pa-
tients bearing thymic neoplasms (17, 18) and a successful
treatment with octreotide was reported in one patient with
thymoma (19). This effect might be mediated by SS-R. Al-
though in a previous study no in vitro evidence of SS-R has
been found in four thymomas, it is well known that there is
a considerable heterogeneity between and within differen-
tiated tumors with respect to the density and the specificity
of SS-R binding sites (32).
We also demonstrated the expression of sst3 in the normal
FIG. 5. A, Effects of SS and octreotide on 3H-thymidine incorporation
in TEC cultures of three different thymuses (nos. 1–3, Table 2). B,
Effects of octreotide on 3H-thymidine incorporation in TEC cultures
of three other thymuses (nos. 4–6, Table 2). Thymic epithelial cells
were incubated in MEM 1 10% FCS during 72 h in quadruplicate
without or with 10 nM of the drugs indicated. Values are expressed as
percentage of 3H-thymidine incorporation by control cells and are
mean 6 SEM; *, P , 0.01 vs. control. o, octreotide; f, somatostatin-14.
Control values of 3H-thymidine incorporation were: 3743.8 6 221.9
(no. 1), 897.1 6 18.6 (no. 2), 492.0 6 23.0 (no. 3), 410.5 6 2.1 (no. 4),
1347.3 6 14.6 (no. 5), 756.3 6 64 (no. 6) cpm.
TABLE 5. Effects of IGF-I and EGF on 3H-Thymidine
incorporation in cultured thymic epithelial cells
Cell culture
3H-Thymidine incorporation (cpm)
Control IGF-I EGF
4 410.5 6 2.1 562.2 6 24.4a 974.6 6 25.8a
5 1347.3 6 14.6 1624.8 6 75.3 3326.8 6 57a
6 756.3 6 64 993.5 6 89.3a 4125.7 6 270.3a
The data represent the mean 6 SEM of four wells per treatment
group.
a P , 0.01 vs. control.
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human thymic tissue, whereas sst3 mRNA was undetectable
in cultured TEC. This may be explained by the fact that this
receptor subtype is expressed by a different epithelial cell
subset or on macrophages. Emerging data regarding signal
transduction pathways linked to SS-R showed a cell cycle-
dependent induction of apoptosis by octreotide (33). Apo-
ptosis seems signaled through the sst3 and associated with
dephosphorylation-dependent conformational change in
wild-type p53 (34). Although controversial data about alter-
ations of p53 expression have been reported in thymic epi-
thelial tumors (35, 36), octreotide-induced apoptosis might
represent an additional mechanism involved in the regula-
tion of cell proliferation in human thymus.
Another important aspect involves the local production
of growth factors and cytokines by TEC and thymocytes
(27, 28, 37). In our study, IGF-I and EGF significantly
stimulated in vitro TEC proliferation. Moreover, in a pre-
liminary experiment, octreotide significantly inhibited
EGF-stimulated cell proliferation. Although an inhibition
of the production of these factors might represent an in-
direct mechanism of action of SS and its analogs, a direct
mechanism involving the phosphoprotein phosphatase ac-
tivity associated to sst2 could not be ruled out (38). Further
studies are required to investigate the precise mechanism
of action of SS in inhibiting growth factors-stimulated TEC
proliferation.
These findings suggest that the SS-R-mediated effects of
SS and octreotide on TEC growth may act via not mutually
exclusive different mechanisms, supporting the physio-
logical paracrine/autocrine role of SS in controlling cell
growth in the human thymic microenvironment. A further
conceptual aspect might be the implication of the role of
the intrathymic production of SS in the main function of
the thymus, namely the maturation and differentiation of
T-lymphocytes. Moreover, a disturbance in these loops
may be important in the pathogenesis of autoimmune and
neoplastic diseases involving this organ. In this respect, a
better understanding of the functional significance of the
presence of SS and SS-R subtypes in the human thymus
might lead to new approaches in the medical management
of these disorders.
In conclusion, we have demonstrated a heterogeneous
expression of SS-R subtypes within the human thymus. Fur-
thermore, TEC respond in vitro to SS and octreotide admin-
istration with an inhibition of cell proliferation. These data,
together with the evidence of other peptide hormones, cy-
tokines and their receptors in the thymus, support the con-
cept of the thymus as the organ where the interactions be-
tween the endocrine and the immune systems are mostly
represented. Future studies should investigate the influence
of SS and its analogs on local cytokine production, which is
known to represent the other arm of the immuno-endocrine
pathway.
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